Neglected tropical diseases (NTDs) are a major cause of death, disability, and economic hardship worldwide, particularly in low- and middle-income countries. While many of these diseases are targeted for control, elimination, or eradication by 2030, achieving those targets will be challenging due to disruptions to programmes related to the COVID-19 pandemic and differences in disease transmission across regions, which requires tailoring interventions to local settings.
The Jenner Institute is conducting a new study, using BCG, the current licensed vaccine against tuberculosis. In this study, they will give BCG a second time to people who have already had BCG once before, and will compare whether giving it by inhalation is better at protecting people against tuberculosis than giving it into the skin
First clinical trial participants received doses of the ChAdOx1 NipahB vaccine over the last week at University of Oxford. UK trial is first step to developing a vaccine against Nipah virus \u2013 a devastating disease mostly found in South-East Asia \u2013 that can be fatal in up to 75% of cases. The milestone clinical trial comes as the global health community marks the 25th anniversary of the first Nipah virus outbreaks. There are still no approved vaccines or treatments for the disease.
A systematic review and individual patient meta-analysis found that malaria chemoprevention after hospital discharge reduces deaths in children recovering from severe anaemia by 70%, and hospital readmission by 55%.
A ground-breaking study, published in Nature Human Behaviour, reveals a significant association between 74 early-life diseases and the likelihood of remaining childless throughout one's life, with 33 of these diseases prevalent in both women and men.
The Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across UK (MBRRACE) collaboration, which is co-led by The Infant Mortality and Morbidity Studies (TIMMS) group at the University of Leicester and the Nuffield Department of Population Health's Perinatal Epidemiology Unit (NPEU), has today published the results of a confidential enquiry into the care of Black and Asian babies born in the UK in 2019.
Oxford Vaccine Group (OVG), which led the rapid clinical development of the Oxford vaccine in COVID-19 in the pandemic, has been awarded a total of \u00a37,788,783 by UK Aid for research into the prevention of five dangerous diseases with epidemic or pandemic potential. The awards will fund research into vaccines against: Chikungunya and mayaro virus, Marburg virus, Plague (Yersinia pestis), Q Fever (Coxiella burneti) and Sudan Ebolavirus.
A new study estimates that nearly 1 in 4 people with P. falciparum malaria in Africa are at risk of receiving too low a dose of artemisinin combination therapies (ACTs), increasing the chance of treatment failure and the risk that malarial parasites develop resistance to the drug they were exposed to.
A new study published in The Lancet Microbe has found that the transfer of antibiotic resistance genes between different bacteria is considerably more widespread than previously thought.
The Global Health Network and Nursing Now Challenge launch The 1000 Challenge, a global research leadership initiative to enable health professionals to ask locally important questions to generate evidence. The initiative aims to change practice and management to improve patient management, care, or treatment in a commitment to advance Health for All.
Researchers from the University of Ghana and Oxford University, including researchers from Oxford Population Health\u2019s Health Economics Research Centre, have shown that small cash incentives increased COVID-19 vaccine uptake in rural Ghana. The findings, published in Nature Medicine, could offer a new strategy for enhancing health interventions in Africa.
In the autumn statement on Wednesday 22 November, the government announced its support for the Rare Therapies Launch Pad, a new programme that will develop regulatory pathways for children with rare conditions to access individualised therapies.
A recent study led by OUCRU researchers highlighted the factors associated with the number of visits to one tertiary public hospital (Hospital for Tropical Diseases in Ho Chi Minh City) that serves as the referral clinic for two-thirds of Vietnam for Hepatitis C virus treatment.
A study led by researchers from Oxford Population Health has described the long-term impact of cigarette consumption in China and assessed the implementation of five key tobacco control strategies advocated by the World Health Organization (WHO). The review is published in The Lancet Public Health.
To mark World Antimicrobial Awareness Week, researchers supported by the Oxford Martin Programme on Antimicrobial Resistance Testing at the University of Oxford have reported advances towards a novel and rapid antimicrobial susceptibility test that can return results within as little as 30 minutes - significantly faster than current gold-standard approaches.
The Pandemic Sciences Institute (PSI) has joined forces with the Science for Africa Foundation and the Mastercard Foundation to launch a call for applications to establish innovative networks of research excellence in epidemic and pandemic sciences across Africa.
Glox Therapeutics, a company pioneering the development of precision antibiotics to combat antimicrobial resistance, has raised \u00a34.3M in early-stage funding to develop effective targeted therapeutics against antibiotic-resistant gram-negative bacteria.
SerenOx Africa aims to address diagnostic gaps for common blood disorders through a testing facility for key underserved patient populations in Tanzania. This facility will also aim to provide early cancer detection for high-risk patients.
CEPI will provide up to $25 million to the University of Oxford to complete early development of prototype vaccines against the Jun\u00edn virus, while also looking to improve manufacturing speed and scale-up of ChAdOx technology.\r\nLearnings could be leveraged to inform vaccine design for related viruses from the Arenavirus family, giving the world a head start in rapidly responding to future outbreaks in as little as 100 days.\r\nFirst project to be initiated under CEPI and University of Oxford\u2019s strategic partnership to accelerate global pandemic preparedness efforts.
![\"Needle](\"https://www.globalhealth.ox.ac.uk/news/forecasting-how-best-to-prevent-control-and-eliminate-neglected-tropical-diseases/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n